MedTrace Logo

Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas

NCT02923011 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-02-19

No results posted yet for this study

Summary

Osteoid osteomas are painful, benign bone tumors that occur most frequently in young males between ages 10 and 20 years. The goal of the proposed study is based on the premise that MRgFUS is noninferior to CT-guided radiofrequency ablation (CTgRFA), in terms of pain reduction following treatment of osteoid osteomas, and offers possible improvements with regards to 1) post-procedural pain, 2) clinical resource utilization, 3) patient experience, and/or 4) adverse events. The data from the current study would provide clinicians important information in deciding between treatment options for ablation of osteoid osteomas.

Conditions

  • Osteoid Osteoma

Interventions

DEVICE

MRgFUS

Magnetic resonance-guided focused ultrasound ablation of osteoid osteoma

DEVICE

CTgRFA

Computed tomography-guided radiofrequency ablation of osteoid osteoma

Sponsors & Collaborators

  • Focused Ultrasound Foundation

    collaborator OTHER

  • Matthew Bucknor

    lead OTHER

Principal Investigators

  • Matthew Bucknor, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-28
Primary Completion
2025-06-30
Completion
2025-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02923011 on ClinicalTrials.gov